AFM13, Antibody of CD30;Antibody of Fc fragment of IgG receptor IIIa

Features and benefits
    Item Number
    Ab175448
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    Ab175448-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,668.90
    Ab175448-5mg
    5mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $4,668.90

    Basic Description

    Product NameAFM13
    SynonymsAFM 13;AFM-13
    Specifications & PurityMoligand™
    GradeMoligand™
    Action TypeANTIBODY
    Mechanism of actionAntibody of CD30;Antibody of Fc fragment of IgG receptor IIIa

    Product Properties

    CASAb175448

    Associated Targets(Human)

    FCGR3A Tclin Low affinity immunoglobulin gamma Fc region receptor III-A (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    TNFRSF8 Tclin Tumor necrosis factor receptor superfamily member 8 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    TNFRSF8 Tclin Tumor necrosis factor receptor superfamily member 8 (0 Activities)
    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Related Documents

    References

    1. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA.  (2014)  A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells..  MAbs,  (3): (728-39).  [PMID:24670809] [10.1021/op500134e]
    2. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C et al..  (2015)  A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma..  Blood,  125  (26): (4024-31).  [PMID:25887777] [10.1021/op500134e]

    Solution Calculators